Endocrine Therapy Response Status Is Necessary for Treatment Planning in HR+/HER2– Early Breast Cancer
Neoadjuvant Nivolumab Plus Carboplatin/Paclitaxel Elicits High pCR Rates in Early-Stage TNBC
Dr Schmid on the Use of Perioperative Pembrolizumab in TNBC
Dr Khan on Optimizing Local Therapy Using MRI and a 12-Gene Expression Assay in DCIS
